Groupe d'Etude en Oncologie du Quebec

Title	Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
Protocole ID	GSK 208750
ClinicalTrials.gov ID	NCT03391778
Cancer Type(s)	Other
Phase	Other
Stage
Study Type
Drug
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
City
Principal Investigator	Dr. Jonathan Noujaim
Coordinator	Olivier Cormier 514-252-3400 poste 5966
Status	Recruiting
Activation Date
Eligibility Criteria	Subjects who have received at least one dose of GSK3377794 in the interventional study. Subjects who have either completed the interventional study or have withdrawn from it. Male or Female subjects. Capable of giving signed informed consent prior to the study participation.
Exclusion Criteria	None

Groupe d'étude en oncologie du Québec